Biography

Lisa Seekircher works as a Postdoc at the Department of Medical Statistics, Informatics and Health Economics of the Medical University of Innsbruck, Austria. She has a background in mathematics and epidemiology with a master’s degree in Technical Mathematics from the University of Innsbruck and a PhD in Neuroscience from the Medical University of Innsbruck. Lisa Seekircher has several experiences in conducting large-scale data analyses with innovative statistical methodologies and developing data management algorithms for complex data structures. Her research mainly focuses on atherosclerosis, cardiovascular and infectious disease outcomes.

 

Selected publications

• Seekircher L, Mühlbacher A, Tschiderer L, Wachter GA, Astl M, Schennach H, Siller A, Willeit P. Anti-HBs Seroprevalence in Blood Donors from Tyrol, Austria. Vaccines (Basel) 2024;12(10):1156. doi: 10.3390/vaccines12101156.
• Seekircher L, Astl M, Tschiderer L, Wachter GA, Penz J, Pfeifer B, Huber A, Afonso PM, Gaber M, Schennach H, Siller A, Willeit P. Anti-Spike IgG antibodies as correlates of protection against SARS-CoV-2 infection in the pre-Omicron and Omicron era. J Med Virol 2024;96(8):e29839. doi: 10.1002/jmv.29839.
• Seekircher L, Tschiderer L, Lind L, Safarova MS, Kavousi M, Ikram MA, Lonn E, Yusuf S, Grobbee DE, Kastelein JJP, Visseren FLJ, Walters M, Dawson J, Higgins P, Agewall S, Catapano A, de Groot E, Espeland MA, Klingenschmid G, Magliano D, Olsen MH, Preiss D, Sander D, Skilton M, Zozulińska-Ziółkiewicz DA, Grooteman MPC, Blankestijn PJ, Kitagawa K, Okazaki S, Manzi MV, Mancusi C, Izzo R, Desvarieux M, Rundek T, Gerstein HC, Bots ML, Sweeting MJ, Lorenz MW, Willeit P. Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment. Eur Heart J Open 2023,3(5):oead089. doi: 10.1093/ehjopen/oead089.
• Seekircher L*, Bánki Z*, Kimpel J, Rössler A, Schäfer H, Falkensammer B, Bante D, Forer L, Schönherr S, Shieldvacc-2 Study Group, Harthaller T, Sacher M, Ower C, Tschiderer L, Ulmer H, Krammer F, von Laer D, Borena W, Willeit P. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial. Lancet Microbe 2023,4(8):e612-e621. doi: 10.1016/S2666-5247(23)00107-6.